1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES

Autor:	D.P. Petrylak, A.A. Azad, R.Z. Szmulewitz, T. Iguchi, N.D. Shore, J. Holzbeierlein, B. Alekseev, N.N. El-Chaar, B. Rosbrook, J. Ma, F. Zohren, G.P. Haas, A. Stenzl, A.J. Armstrong
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1183-S1184
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c1fd067587485d60d354d14bcd13c2b4 https://doi.org/10.1016/j.annonc.2022.07.1884 Zobrazit plný text záznamu